Johnson & Johnson‘s commitment to Italy is stronger than ever: the company has recently announced a 580-million-euro investment over the next five years to increase production capacity and support the development of innovative therapies. This investment is a clear sign of the pharmaceutical company’s strong roots in Italy, particularly in Lombardy.
The new Milan headquarters, inaugurated in the Bicocca district, is a symbol of Johnson & Johnson’s focus on sustainability. The headquarters has been designed to promote collaboration and dialogue with all stakeholders in the healthcare system, reflecting the company’s ambition to meet the care needs of all patients. The ‘Outstanding Experience’ certification obtained for the workplace environment further validates the company’s commitment to creating a high-performance work environment.
The decision to create a new hub in Milan is part of a global renewal strategy that Johnson & Johnson is implementing, including a recent rebranding initiative. The company’s investment in Italy further emphasizes its dedication to delivering innovative therapies to patients worldwide. The Latina plant, opened in 1982, is a testament to Johnson & Johnson’s long-standing presence in Italy.
In the next 10 years, the company expects significant progress in the field of medicine. The company’s commitment to developing innovative treatments, as demonstrated by the J&J Innovative Medicine segment, is unwavering. With 80 molecules developed, 18 of which are on the WHO’s list of essential medicines, Johnson & Johnson has made significant contributions to the treatment of diseases previously considered incurable. The pharmaceutical component of the Johnson & Johnson Group, J&J Innovative Medicine, is dedicated to addressing unmet medical needs in six different therapeutic areas. The company’s investment in research and development, totaling 15 billion dollars in 2023 alone, underscores its commitment to innovation in healthcare.
The investment of 580 million euros in Italy will not only increase production capacity but also support the development of skills for the future. With a focus on delivering the medicine of the future, Johnson & Johnson aims to positively impact the health of humanity through its expertise in science and technology.
As it continues to invest in Italy, the pharmaceutical company is poised to play a crucial role in shaping the future of healthcare. With a history of groundbreaking innovations and a commitment to addressing unmet medical needs, Johnson & Johnson’s presence in Italy is set to bring new advancements in medicine and improve the lives of patients worldwide.
Nakamoto, the Bitcoin treasury company led by CEO David Bailey, has announced that it officially…
The connection between Italy and the United States is being reinforced under the banner of…
Now in his fifth term, CEO Claudio Descalzi has successfully reshaped Eni into a leading…
Sabelli Group targets global growth with frozen mozzarella, investing €45M by 2028 to boost exports…
Factorial Energy to go public via SPAC merger with Cartesian Growth III, raising $376M to…
Italy invests in semiconductors: Fondazione Chips.it drives chip design, advanced labs and EU projects to…